Raymond James & Associates Tekla Life Sciences Investors Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Tekla Life Sciences Investors stock. As of the latest transaction made, Raymond James & Associates holds 29,755 shares of HQL stock, worth $396,336. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,755
Previous 26,322
13.04%
Holding current value
$396,336
Previous $354,000
14.41%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding HQL
# of Institutions
80Shares Held
8.52MCall Options Held
0Put Options Held
0-
Saba Capital Management, L.P. New York, NY2.46MShares$32.8 Million0.58% of portfolio
-
Morgan Stanley New York, NY484KShares$6.45 Million0.0% of portfolio
-
1607 Capital Partners, LLC Richmond, VA481KShares$6.41 Million0.54% of portfolio
-
Allspring Global Investments Holdings, LLC431KShares$5.75 Million0.01% of portfolio
-
Aqr Arbitrage LLC Greenwich, CT387KShares$5.16 Million0.32% of portfolio
About TEKLA LIFE SCIENCES INVESTORS
- Ticker HQL
- Exchange NYSE
- Sector Financial Services
- Industry Asset Management
- Description
- Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical...